NCT05956522View on ClinicalTrials.gov

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

January 13, 2023

Conditions
Healthy
Interventions
DRUG

Test Empagliflozin And Linagliptin Tablets

specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd

DRUG

Reference Empagliflozin And Linagliptin tablets

specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG

Trial Locations (1)

266003

The Affiliated Hospital of Qingdao University Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER